Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318903 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00318903: Completed Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT00318903 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00318903, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
There is a need for more effective therapy for patients following surgery for esophageal carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in this disease. There is interest in the combination of these two active agents plus radiotherapy.
Interventions
- DRUG Irinotecan (drug)
- DRUG Taxotere (drug)
- PROCEDURE Radiotherapy (procedure)
- PROCEDURE Esophagectomy (procedure)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00318903 record still lists
NCT00318903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 4 interventions - of which Irinotecan (drug) is the first listed.
NCT00318903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00318903 about?
NCT00318903 is a clinical study titled "Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer". There is a need for more effective therapy for patients following surgery for esophageal carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in this disease. There is interest in the combination of these two active agents plus radiotherapy.
What is the current status of trial NCT00318903?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2002-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00318903?
The interventions under investigation include: Irinotecan (drug) (DRUG), Taxotere (drug) (DRUG), Radiotherapy (procedure) (PROCEDURE), Esophagectomy (procedure) (PROCEDURE).
Who is sponsoring clinical trial NCT00318903?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00318903's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia